As the options for glucose-lowering medications for patients with type 2 diabetes have expanded, the choices for physicians and patients have become more difficult. Owing to a 2008 US Food and Drug Administration mandate, more than 20 randomized, mostly placebo-controlled, cardiovascular outcomes trials (CVOTs) of new glucose-lowering medications have been published in the last 5 years,1 prompting a shift in prescribing recommendations for medication management in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.2 One of the most important findings to emerge from this set of trials—regarding the cardiovascular safety of sulfonylureas—is published in this issue of JAMA. A second article, a retrospective cohort study also published in this issue, expands current understanding of the cardiovascular safety of metformin and sulfonylurea use in early chronic kidney disease.
Wexler DJ. Sulfonylureas and Cardiovascular Safety: The Final Verdict? JAMA. 2019;322(12):1147–1149. doi:https://doi.org/10.1001/jama.2019.14533
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: